HIV treatments core to company’s product offerings
Viatris is one of the world's largest producers of active pharmaceutical ingredients (API) used for manufacturing generic antiretroviral therapies, a key ingredient in HIV/AIDS treatment. This represents activities previously under control of Mylan. In 2018, the company, then Mylan, announced that the introduction of its FDA-approved triple combination once-daily HIV treatment. By acquiring Mylan’s vertically integrated supply chain, Viatris is well positioned to enter the biosimilar market as several blockbuster biologics come off patent over the five years to 2026.
Balance Sheet|StructuralIn response to volatile demand in the wake of the first COVID-19 surge, the company undertook a comprehensive cost reduction program, aimed at shoring up labor and supply costs.
Lorem Ipsum text header Report Title
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas non leo lacinia, consectetur ipsum non, pretium augue. Vestibulum accumsan dignissim massa, eu scelerisque mi malesuada ut. Aliquam scelerisque facilisis nisl ac varius. Nunc luctus nunc vel eros iaculis, vitae tristique ante fringilla. Ut vitae vulputate est, vel lacinia nisi. Curabitur eget nulla vitae mi faucibus imperdiet. Cras sagittis arcu eu diam pharetra iaculis eget sit amet risus. Morbi eget turpis ut diam commodo congue id eu lacus.
Cras sagittis arcu eu diam pharetra iaculis eget sit amet risus. Morbi eget turpis ut diam commodo congue id eu lacus.